Aged mice treated with intranasal mRNA drops showed memory performance comparable to younger animals and roughly 2.4 times more cells expressing a neurogenesis-related marker than untreated controls. Those results, published in the journal Advanced Science, come from a University of Sydney research team testing a nasal delivery platform for a brain-protective protein.

The system packages mRNA instructions inside lipid nanoparticles, a fatty-shell delivery technology also used in some COVID-19 mRNA vaccines, and administers them as nose drops. Rather than delivering a protein directly, the drops instruct nasal epithelial cells to manufacture brain-derived neurotrophic factor, known as BDNF, locally.
BDNF supports neuron survival, synaptic function, and the formation of new neurons, a process called neurogenesis. Delivering BDNF as a conventional protein is impractical because it degrades rapidly in nasal mucus and reaches the brain in limited quantities. The mRNA approach turns the nose into a short-term production facility, with detectable BDNF expression lasting up to four days per dose.
Connections between nasal tissue and the central nervous system offer a proposed route for locally produced BDNF to reach the brain. That path may reduce dependence on crossing the blood-brain barrier, the tightly regulated membrane that blocks most large molecules from entering brain tissue.

In aged mice roughly 18 months old and already showing age-related cognitive decline, treated animals performed significantly better than untreated controls on tests of working memory, spatial memory, and object recognition. Their performance reached levels comparable to younger mice in reported assessments.
The team also tested the drops in 5xFAD mice, a genetically engineered Alzheimer’s disease model. Animals receiving twice-weekly treatment beginning around the onset of Alzheimer’s-like pathology showed no further cognitive decline at the study’s assessment point. Hippocampal neurogenesis markers also increased in treated animals.
One finding carries particular weight for how the treatment might eventually fit into Alzheimer’s care: the drops did not appear to reduce amyloid plaques, the protein deposits associated with the disease. The cognitive improvements are hypothesized to stem from supporting neuronal health and plasticity rather than clearing pathology, which would position this approach as a potential complement to plaque-targeting therapies rather than a replacement.
The results are specific to mice. Human and mouse nasal anatomy differ substantially, and improved performance on mouse memory tasks cannot be assumed to translate to human benefit.
Researchers have not established whether the mRNA can be delivered safely and consistently in human nasal tissue, or how much BDNF reaches a human brain. Whether repeated dosing causes inflammation or other adverse effects also remains unknown.
Additional animal safety, dosing, and manufacturing studies are required before any human testing can begin. The University of Sydney team has stated it hopes to move toward clinical trials potentially within two years, contingent on completing those prerequisite studies and securing regulatory approval.






























